Physician profile
John E Dudzinski
NPI 1174580070
$27,665.64
in general payments reported to CMS, 2019-2025
59 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,811 · 2020: $8,962 · 2021: $3,127 · 2022: $2,781 · 2023: $2,574 · 2024: $2,202 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,912 · Education: $72.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,911.50 |
| Education | $72.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,771.78 | 2019-2025 | |
| Lilly USA, LLC | $1,586.20 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $1,336.30 | 2019-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $1,225.45 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,137.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,118.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $999.54 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $787.44 | 2019-2025 | Synjardy, Jardiance, Stiolto Respimat |
| Amgen INC. | $679.44 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $478.22 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $439.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $430.53 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $394.76 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.91 | 2019-2023 | Trintellix |
| Madrigal Pharmaceuticals | $297.23 | 2025 | Rezdiffra |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dudzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.